Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Endosense logo — company profile

Endosense

Founded 2003 Switzerland Meyrin, Switzerland 1 employees Series C Total: $144.00M Biotechnology, Health Care +2

General Information

Company Name Endosense
Founded Year 2003
Location Switzerland Meyrin, Switzerland +1
Employees 1
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series C
Social

Get notified when Endosense moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Endosense

Endosense is a Switzerland-based medical technology company that focuses on enhancing the effectiveness, safety, and reproducibility of catheter ablation for treating cardiac arrhythmias. Founded in 2003, the company has developed the TactiCath Quartz®, the pioneering force-sensing ablation catheter that provides real-time, objective feedback on contact force during the procedure. Clinical studies have demonstrated that utilizing contact force during ablation can reduce procedure time and minimize PV gaps at 3-month invasive follow-up. The most recent investment in Endosense was a Fr.37.40M Series C funding round on 27 November 2013. The investors in this round included GIMV, VI Partners, NeoMed Management, Sectoral Asset Management, Ysios Capital, NGN Capital, Andera Partners, and Initiative Capital Romandie. This investment reaffirms the confidence of the investor community in the potential of Endosense and its innovative technology to make significant advancements in the field of cardiac arrhythmia treatment.

Taxonomy: catheter ablation, cardiac arrhythmias, clinical studies, contact force, TactiCath Quartz, force-sensing ablation, procedure efficacy, patient safety, reproducibility, heart wall perforation risk, recurrence risk, ablation catheter, real-time measurement, force control

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		27 Nov 2013
Series C •••••• - 06 Mar 2013
Series C •••••• 2
Investor Investor
27 Nov 2012
Series B •••••• - 27 Oct 2009
Series A •••••• - 21 Nov 2005

FAQ About Endosense

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has conducted numerous clinical studies and has shown that using contact force during ablation can reduce procedure time...
Endosense was founded in 2003.
Endosense is headquartered in Meyrin, Switzerland.
Endosense operates in the following industries: Biotechnology, Health Care, Health and Wellness, Medical Devices.
Endosense has approximately 1 employees.
Endosense has completed 5 funding rounds, raising a total of $144.00M. The latest funding stage is Series C.

We're actively collecting intelligence on Endosense.

Track Endosense to get notified

Don't just browse. Track.

Signal Tracker monitors Endosense and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes